A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients with Essential Hypertension and Type 2 Diabetes in Asia.

"Disclosure At first, Takeda Pharmaceutical Company Ltd. was involved in the study design, protocol development, data collection, and review and analysis of the data, as well as submission the original manuscript. Later, Celltrion Asia Pacific Pte. Ltd. had relation to resubmission of the revised manuscript and sponsored a part of publication of this article. Conflicts of Interest The authors declare no conflicts of interest regarding the publication of this paper."

"The authors thank the patients and their caregivers in addition to the investigators and their teams who contributed to this study. Clinical study was sponsored by Celltrion Asia Pacific Pte. Ltd. and Takeda Pharmaceutical Company Ltd."

"This study was registered at ClinicalTrials.gov (NCT02517866; https://clinicaltrials.gov/ct2/show/NCT02517866) on August 7, 2015, and was conducted in accordance with the protocol, the ethical principles that have their origin in the Declaration of Helsinki, the ICH E6 GCP guidance, and all applicable regulations. The study was reviewed and approved by the local or central IRBs/IECs of all study sites. Each subject (or the subject's legally authorized representative) signed and dated the informed consent form before undergoing any study participation."